Increased sensitivity to cytosine arabinoside in human leukemia by c-raf-1 antisense oligonucleotides

Anti-Cancer Drugs

Volumn 12, Issue 4, 2001, Pages 325-329

  Funato, Tadao ^a   Kozawa, Kanoko ^a   Fujimaki, Shinichi ^a   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Antisense oligonucleotides; c raf 1; Cytosine arabinside; Leukemia

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTARABINE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, NORTHERN; CELL DIVISION; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LEUKEMIA; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 0035014965     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200104000-00004     Document Type: Article

References (24)

1. 1. Williams NG, Roberts TM. Signal transduction pathways involving the Raf proto-oncogene. Cancer Met Rev 1994; 13: 105-16.
2. 2. Cross TG, Scheel-Toellner D, Henriquez NV, et al. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000; 256: 34-41.
3. 3. Strom SM, Brennscheidt U, Sithanandam G, et al. Raf oncogenes in carcinogenesis. Crit Rev Oncol 1990; 2: 1-8.
4. 4. Trench GC, Southal M, Smith P, et al. Allelic variation of the c-raf-1 proto-oncogene in human lymphoma and leukemia. Oncogene 1989; 4: 507-10.
5. 5. Blagosklonny MV, Giannakakou P, El-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130-5.
6. 6. Kim SH, Park JI, Chung BS, et al. Inhibition of MDR1 gene expression by H-87, a selective inhibitor of cAMP-dependent protein kinase. Cancer Lett 1993; 74: 37-41.
7. 7. Cornwell MM, Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 1993; 268: 15347-50.
8. 8. Hass R, Hirano M, Kharbanda S, et al. Resistance to phorbol ester-induced differentiation of a U-937 myeloid leukemia cell variant with a signaling defect upstream to Raf-1 kinase. Cell Growth Different 1993; 4: 657-63.
9. 9. Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligonucleotide targeted against c-raf kinase. Nat Med 1996; 2: 668-75.
10. 10. Skorski T, Nieborowska-Skorska M, Szczylik C, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 1995; 55: 2275-8.
11. 11. Soldatenkov VA, Dritschilo A, Wang FH, et al. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J Sci Am 1997; 3: 13-20.
12. 12. Gokhale PC, McRae D, Monia BP, et al. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 1999; 9; 191-201.
13. 13. Funato T, Satou J, Nishiyama Y, et al. In vitro leukemia cell models of Ara-C resistance. Leuk Res 2000; 24: 535-41.
14. 14. Bonner T, Oppermann H, Seeburg P, et al. The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res 1986; 14: 1009-15.
15. 15. Scanlon KJ, Newman EM, Lu Y, et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells, Proc Natl Acad Sci USA 1986; 83: 8923-5.
16. 16. Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase, Drug Metab Disp 1997; 25: 1272-81.
17. 17. Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligonucleoxynucleotide (CGP69846A) after intravenous and subcutaneous administration. Biochem Pharmcol 1997; 54: 657-68.
18. 18. Patel S, Wang FH, Whiteside TL, et al. Constitutive modulation of Raf-1 protein kinase is associated with differential gene expression of several known and unknown genes. Mol Med 1997; 3: 674-85.
19. + currents via Ras-and Raf-1-dependent pathway in cultured oligodendrocytes. J Neurosci 1998; 18: 8712-9.
20. 20. Chu-Chung YS. Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment, Pharmacol Ther 1999; 82: 437-49.
21. 21. Flasshove M, Strumberg D, Ayscue L, et al. Structure analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994; 8: 780-5.
22. 22. Stevenson JP, Yao KS, Gallagher M, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 1999; 17: 2227-36.
23. 23. Cunningham CC, Holmlund JT, Schiller JH, et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000; 6: 1626-31.
24. 24. Britten RA, Perdue S, Eshpeter A, et al, Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep 2000; 7: 821-5.